Ronald van Vollenhoven

71.0k citations

512 papers · 27.7k indexed · 13 hit papers · h-index 80

Rheumatology top 0.01%
Immunology top 0.05%
Hematology top 0.05%
Radiology, Nuclear Medicine and Imaging top 0.1%
Genetics top 0.05%

Co-authors: Paul Emery Roy Fleischmann Karel Pavelká Lars Klareskog Edward Keystone Désirée van der Heijde Stanley Cohen Gerd R Burmester
Topics: Rheumatoid Arthritis Research and Therapies (308 papers)Systemic Lupus Erythematosus Research (247 papers)Chronic Lymphocytic Leukemia Research (125 papers)
Cited by: Rheumatology Hematology Immunology
Journals: New England Journal of Medicine The LancetSHILAP Revista de lepidopterología
Partner nations: Sweden United States Netherlands

In The Last Decade

Ronald van Vollenhoven

484 papers receiving 26.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

2005 1.4k citations Karel Pavelká, Ronald van Vollenhoven et al. profile →
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

2011 1.1k citations Richard Furie, Andreas Schwarting et al. profile →
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

2008 866 citations Paul Emery, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases profile →
Systemic lupus erythematosus

2016 849 citations Murray B. Urowitz, Ronald van Vollenhoven et al. profile →
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

2006 783 citations Paul Emery, Ronald van Vollenhoven et al. profile →
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

2012 739 citations Ronald van Vollenhoven et al. profile →
Tofacitinib versus Methotrexate in Rheumatoid Arthritis

2014 598 citations Ronald van Vollenhoven et al. profile →
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

2013 502 citations Cem Gabay, Paul Emery et al. profile →
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

2020 195 citations Josef S Smolen, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

2020 180 citations Ronald van Vollenhoven, Gerd R Burmester et al. Annals of the Rheumatic Diseases profile →
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Eric F. Morand, Ronald van Vollenhoven et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Eric F. Morand, Ronald van Vollenhoven et al. profile →

Peers

Countries citing papers authored by Ronald van Vollenhoven

Since Specialization

Citations

This map shows the geographic impact of Ronald van Vollenhoven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald van Vollenhoven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald van Vollenhoven more than expected).

Fields of papers citing papers by Ronald van Vollenhoven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald van Vollenhoven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald van Vollenhoven. The network helps show where Ronald van Vollenhoven may publish in the future.

Co-authorship network of co-authors of Ronald van Vollenhoven

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald van Vollenhoven. A scholar is included among the top collaborators of Ronald van Vollenhoven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald van Vollenhoven. Ronald van Vollenhoven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial 2025 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),Gertjan Wolbink,Michael T. Nurmohamed,Maarten Boers,Femke Hooijberg,Theo Rispens,Annick de Vries,Ronald van Vollenhoven,Sofía Ramiro,Noortje van Herwaarden,Bart J. F. van den Bemt,Alfons A den Broeder	0
2	POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL 2024 ·Annals of the Rheumatic Diseases ·Ronald van Vollenhoven,Joseph F. Merola,(unknown),Piotr Leszczyński,M C Pike,Shirley A. Pomponi,(unknown),(unknown),(unknown),(unknown),(unknown),Eric F. Morand	0
3	LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis 2024 ·SHILAP Revista de lepidopterología ·Ronald van Vollenhoven,Eric F. Morand,Richard Furie,Kenneth Kalunian,Raj Tummala,Gabriel Abreu,Hussein Al‐Mossawi,Catharina Lindholm	2
4	Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study 2024 ·RMD Open ·(unknown),(unknown),Daisy Vedder,(unknown),Anna Rudin,Dan Nordström,Björn Guðbjörnsson,(unknown),Till Uhlig,Espen A. Haavardsholm,Gerður Gröndal,Merete Lund Hetland,Marte Schrumpf Heiberg,Mikkel Østergaard,Kim Hørslev‐Petersen,Jon Lampa,Ronald van Vollenhoven,Aleksandra Antovič,Michael T. Nurmohamed	0
5	OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB 2023 ·Annals of the Rheumatic Diseases ·Eric F. Morand,Ronald van Vollenhoven,Richard Furie,Kenneth Kalunian,(unknown),Gabriel Abreu,(unknown),Hussein Al‐Mossawi	5
6	AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE 2023 ·Annals of the Rheumatic Diseases ·(unknown),Richard Furie,Maria Dall’Era,Andrew S. Bomback,Andreas Schwarting,Ming‐Hui Zhao,Ian N Bruce,Munther A. Khamashta,Bernard Rubin,(unknown),Maxine Daniels,Roger A. Levy,Ronald van Vollenhoven,Murray B. Urowitz	1
7	Clinical evaluation of optical spectral transmission imaging for detection of disease activity in rheumatoid arthritis 2023 ·Scandinavian Journal of Rheumatology ·(unknown),Mies A. Korteweg,Laurette van Boheemen,Ronald van Vollenhoven,Michael T. Nurmohamed,(unknown)	1
8	An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis? 2022 ·Lara D. Veeken ·(unknown),(unknown),Marion C Kortekaas,Marloes Verstappen,Sarah Ohrndorf,Elise van Mulligen,Ronald van Vollenhoven,Dirkjan van Schaardenburg,Pascal H P de Jong,Annette H M van der Helm–van Mil	8
9	Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials 2022 ·Lara D. Veeken ·Ian N Bruce,Ronald van Vollenhoven,Eric F. Morand,Richard Furie,Susan Manzi,William B. White,Gabriel Abreu,Raj Tummala	20
10	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria 2022 ·Lupus Science & Medicine ·Ronald van Vollenhoven,Anca Askanase,Andrew S. Bomback,Ian N Bruce,(unknown),Maria Dall’Era,(unknown),Roger A. Levy,Andreas Schwarting,(unknown),Murray B. Urowitz,Ming‐Hui Zhao,Richard Furie	31
11	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine 2021 ·RMD Open ·Willem F. Lems,Maarten Boers,Ronald van Vollenhoven,Michael T. Nurmohamed	2
12	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis 2019 ·Annals of the Rheumatic Diseases ·Lisa Ehlers,Johan Askling,(unknown),(unknown),Maurizio Cutolo,Bhaskar Dasgupta,Christian Dejaco,William G Dixon,Nils Feltelius,Axel Finckh,Kate Gilbert,Sarah Mackie,Alfred Mahr,Eric L. Matteson,Lorna Neill,Carlo Salvarani,Wolfgang Schmidt,Anja Strangfeld,Ronald van Vollenhoven,Frank Buttgereit	57
13	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay 2019 ·Science Translational Medicine ·(unknown),(unknown),(unknown),M. Hart,Pleuni Ooijevaar‐de Heer,Karien Bloem,Michael T. Nurmohamed,Ronald van Vollenhoven,Maarten Boers,(unknown),Catherine Smith,Gertjan Wolbink,Theo Rispens	41
14	Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback. 2018 ·PubMed ·(unknown),Ronald van Vollenhoven,Reinier Akkermans,Lise M Verhoef,Marlies Hulscher,Alfons A den Broeder	10
15	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial 2017 ·Annals of the Rheumatic Diseases ·(unknown),C. Krieckaert,Michael T. Nurmohamed,Ronald van Vollenhoven,Theo Rispens,Maarten Boers,Gertjan Wolbink	53
16	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis 2017 ·Annals of the Rheumatic Diseases ·J. Nam,Kaoru Takase-Minegishi,Sofía Ramiro,Katerina Chatzidionysiou,Josef S Smolen,Désirée van der Heijde,J. W. J. Bijlsma,Gerd R Burmester,Maxime Dougados,Marieke Voshaar,Ronald van Vollenhoven,Robert Landewé	183
17	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study 2016 ·Annals of the Rheumatic Diseases ·Paul Emery,Clifton O. Bingham,Gerd R Burmester,Vivian P. Bykerk,Daniel E. Furst,Xavier Mariette,Désirée van der Heijde,Ronald van Vollenhoven,Catherine Arendt,Irina Mountian,O. Purcaru,Daljit Tatla,Michael E. Weinblatt,(unknown)	72
18	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study 2015 ·Annals of the Rheumatic Diseases ·Josef S Smolen,Michael E. Weinblatt,Désirée van der Heijde,William F. C. Rigby,Ronald van Vollenhoven,Clifton O. Bingham,Melissa Veenhuizen,Anne Gill,Fangyi Zhao,Wendy Komocsar,(unknown),Robert Ortmann,Chin Lee	27
19	In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial. 2012 ·Research at the University of Copenhagen (University of Copenhagen) ·Ronald van Vollenhoven,Mikkel Østergaard,Marjatta Leirisalo‐Repo,(unknown),(unknown),(unknown),Karen Hutchinson,Karin Franck‐Larsson	3
20	Efficacy of different doses of rituximab for the treatment of rheumatoid arthritis: Data from the CERERRA collaboration. 2011 ·Research at the University of Copenhagen (University of Copenhagen) ·Katerina Chatzidionysiou,Elisabeth Lie,Е. Л. Насонов,G. Lukina,Merete Lund Hetland,Ulrik Tarp,I. Ancuta,Karel Pavelká,Dan Nordström,Cem Gabay,Helena Canhão,Matija Tomšič,(unknown),Juan J. Gómez‐Reino,Tore K Kvien,Ronald van Vollenhoven	1

About Ronald van Vollenhoven

Ronald van Vollenhoven is a scholar working on Rheumatology, Genetics and Hematology, having authored 512 papers that have together received 27.7k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (308 papers), Systemic Lupus Erythematosus Research (247 papers) and Chronic Lymphocytic Leukemia Research (125 papers). The work is most often cited by research in Rheumatology (20.6k citations), Hematology (6.8k citations) and Immunology (10.0k citations). Ronald van Vollenhoven has collaborated with scholars based in Sweden, United States and Netherlands. Frequent co-authors include Paul Emery, Roy Fleischmann, Karel Pavelká, Lars Klareskog, Edward Keystone, Désirée van der Heijde, Stanley Cohen, Gerd R Burmester, Robert Landewé and James L. McGuire. Their work appears in journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact